Evidence map›Paper›PMID 36164760›Full record

ArticleCurrent medical research and opinion2022

Lowering hemoglobin A1c level to less than 6.0% in people with type 2 diabetes may reduce major adverse cardiovascular events: a Bayesian's narrative.

Hui Shao, Jingchuan Guo, Neda Laiteerapong, Shichao Tang, Vivian Fonseca, Lizheng Shi, Ping Zhang

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Current medical research and opinion, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hui ShaoDepartment of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, FL, USA.
Jingchuan GuoDepartment of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, FL, USA.
Neda LaiteerapongDepartment of Medicine, University of Chicago, Chicago, IL, USA.
Shichao TangDivision of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Vivian FonsecaDepartment of Medicine and Pharmacology, School of Medicine, Tulane University, New Orleans, LA, USA.
Lizheng ShiDepartment of Health Policy and Management, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA, USA.
Ping ZhangDivision of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Funding

Research Design, Data, and Analytics CoreP30DK092949 · NIDDK · UNIVERSITY OF CHICAGO · PI MILDA Renne SAUNDERS · 2011 to 2026
$10.0M
Supplement of NIDDK R01 newer GLDs and Clinical OutcomesR01DK133465 · NIDDK · UNIVERSITY OF FLORIDA · PI GUO, JINGCHUAN, SHAO, HUI · 2022 to 2025
$2.8M
NIDDK NIH HHS P30 DK092949NIDDK NIH HHS R01 DK133465
6 · The paper itself

Abstract

Whether lowering the hemoglobin A1c to <6.0% in patients with type 2 diabetes can reduce the risk of cardiovascular disease (CVD) remains under debate. The ACCORDION and the VADT studies both found reductions in the primary CVD composite associated with intensive glycemic control, though the difference is not statistically significant. However, the lack of significance is often overinterpreted as non-effective: a

Indexed as

Cardiovascular DiseasesDiabetes Mellitus, Type 2Bayes TheoremGlycated HemoglobinHumansGlycated HemoglobinA1c goalACCORDIONrisk of cardiovascular diseaseVADT-15

Identifiers

PMID36164760
PMCPMC9737997

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.